Dapagliflozin: more than just another oral glucose-lowering agent?
about
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose LoweringManagement of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.Dapagliflozin: a review on efficacy, clinical effectiveness and safety.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Industrial natural product chemistry for drug discovery and development.Combination therapy for type 2 diabetes: dapagliflozin plus metformin.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.Gout and diabetes: a common combination.Tofogliflozin: the road goes ever on.Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?
P2860
Q26775823-2B0FA79E-B27B-4155-9F34-51F598AE6307Q35073384-9C233502-D5F0-4974-88A0-B8AD4BBE80C0Q36828139-52A10424-A298-4311-85EE-2F5BB56ABBEDQ38057810-344488AD-BA58-4926-A12A-4DF9FE5C4D12Q38126109-4B960821-D31E-4F9D-B6E8-B3BD0105893FQ38154186-8D2BF054-942A-4564-B36D-1795B23361E5Q38633198-1B7E195D-2C3E-4E03-A894-98C6A15C5068Q38824557-EB4501B8-F36B-4163-A296-F562175668E4Q39776464-9D60AF89-263D-4357-9A2E-8153FBB6CE24Q42658161-8B96B712-0574-42B6-BA8F-D2CA6CBCD480Q45348074-CB2F6F31-9FD3-4125-89B5-F0B597113986Q47701628-1387B6A0-4C74-4758-BA62-30594EF83C4BQ48664757-23013572-EF7C-4E61-9642-D833B76EA567Q51285159-A58F5C70-75F8-46B3-B3A6-8151413EE0CBQ53633169-FF169299-2EC8-47B4-8214-30BA0E96C145
P2860
Dapagliflozin: more than just another oral glucose-lowering agent?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dapagliflozin: more than just another oral glucose-lowering agent?
@en
Dapagliflozin: more than just another oral glucose-lowering agent?
@nl
type
label
Dapagliflozin: more than just another oral glucose-lowering agent?
@en
Dapagliflozin: more than just another oral glucose-lowering agent?
@nl
prefLabel
Dapagliflozin: more than just another oral glucose-lowering agent?
@en
Dapagliflozin: more than just another oral glucose-lowering agent?
@nl
P1476
Dapagliflozin: more than just another oral glucose-lowering agent?
@en
P2093
Niki Katsiki
Nikolaos Papanas
P304
P356
10.1517/13543784.2011.539558
P407
P577
2010-12-01T00:00:00Z